论文部分内容阅读
许多糖尿病性角膜上皮病变,特别是发生在治疗增殖性糖尿病性视网膜病变的玻璃体手术等内眼手术后的糖尿病性角膜上皮病变,文献早有报道。这类角膜上皮病变可持续数周,且难治疗。其发病机理迄今不明,推测可能是山梨醇通路的第一个酶,即醛糖还原酶的作用,正如在其它组织中发生糖尿病并发症时所见一样。免疫组织化学研究表明,醛糖还原酶存在于角膜上皮的基底层。实验研究也证实,对因链脲佐菌素(streptozotocin)而诱发糖尿病或半乳糖血症的病鼠,醛糖还原酶抑制剂能有效地促进其角膜上皮再生。作者报告2例糖尿病性角膜上皮病变,传统的药物疗法无效,采用新的醛糖还原酶抑制
Many diabetic corneal epithelial lesions, especially in the treatment of proliferative diabetic retinopathy and other vitreous surgery after intraocular surgery such as diabetic corneal epithelial lesions, the literature has long been reported. This type of corneal epithelial lesions can last for several weeks and is refractory. Its pathogenesis has so far been unknown, suggesting that it may be the first enzyme in the sorbitol pathway, the role of aldose reductase, as seen in other tissues when diabetic complications occur. Immunohistochemical studies have shown that aldose reductase is present in the basal layer of the corneal epithelium. Experimental studies have also confirmed that aldose reductase inhibitors are effective in promoting the regeneration of corneal epithelium in diseased mice induced by streptozotocin for diabetes or galactosemia. The authors report 2 cases of diabetic corneal epithelial lesions, the traditional drug therapy is invalid, the use of new aldose reductase inhibition